Ex-Operation Warp Speed chief Slaoui removed from GlaxoSmithKline board after harassment allegation

A top adviser to the Trump administration's Operation Warp Speed vaccine development program has been removed from his post on the GlaxoSmithKline board of directors following accusations of sexual harassment.

In February, the pharmaceutical firm received a letter accusing chief Warp Speed adviser Dr. Moncef Slaoui of inappropriate behavior, including sexual harassment, several years ago. 

On Wednesday, the firm announced that Slaoui had been removed from his post as chairman of the Galvani Bioelectronics board, owned by GlaxoSmithKline.

Attempts to reach Slaoui were unsuccessful.There have so far been no reports about the specifics of the allegation. 

"The investigation of Dr. Slaoui’s conduct substantiated the allegations and is ongoing. Dr. Slaoui’s behaviors represent an abuse of his leadership position and violate our company policies, our values, and our commitment to Trust – a commitment I know is shared by all of you," firm CEO Emma Walmsley wrote to employees, according to news reports.